A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
Public ClinicalTrials.gov record NCT06267846. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Study identification
- NCT ID
- NCT06267846
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 73 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 20, 2024 (Actual)
- Primary completion
- Jul 25, 2025 (Actual)
- Completion
- Sep 11, 2025 (Actual)
- Last update posted
- Jul 17, 2026
2024 – 2025
United States locations
- U.S. sites
- 13
- U.S. states
- 7
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neurocrine Clinical Site | Little Rock | Arkansas | 72211 | — |
| Neurocrine Clinical Site | Rogers | Arkansas | 72758 | — |
| Neurocrine Clinical Site | Lemon Grove | California | 91945 | — |
| Neurocrine Clinical Site | Long Beach | California | 90806 | — |
| Neurocrine Clinical Site | Hollywood | Florida | 33024 | — |
| Neurocrine Clinical Site | Maitland | Florida | 32751 | — |
| Neurocrine Clinical Site | Decatur | Georgia | 30030 | — |
| Neurocrine Clinical Site | Savannah | Georgia | 31405 | — |
| Neurocrine Clinical Site | Gaithersburg | Maryland | 20877 | — |
| Neurocrine Clinical Site | Dayton | Ohio | 45439 | — |
| Neurocrine Clinical Site | North Canton | Ohio | 44730 | — |
| Neurocrine Clinical Site | Houston | Texas | 77008 | — |
| Neurocrine Clinical Site | Richardson | Texas | 75080 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06267846, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2026 · Synced Oct 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06267846 live on ClinicalTrials.gov.